(19)

(11)

EP 4 824 093 A1

(12)

(43) Date of publication: 21.10.2026 Bulletin 2026/43 (21) Application number: 24828975.3 (22) Date of filing: 11.12.2024

(51) International Patent Classification (IPC):  C07K 16/28(2006.01) A61K 39/395(2006.01) C07K 16/30(2006.01) A61P 35/00(2006.01) (52) Cooperative Patent Classification (CPC): C07K 16/3092; C07K 16/2809; C07K 2317/31; A61P 35/00; A61K 2039/505; C07K 2317/33; A61K 2039/507; C07K 16/2818 (86) International application number: PCT/US2024/059495 (87) International publication number: WO 2025/128652 (19.06.2025 Gazette 2025/25)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: GE KH MA MD TN (30) Priority: 12.12.2023 US 202363608922 P (71) Applicant: Regeneron Pharmaceuticals, Inc. Tarrytown, NY 10591 (US)	(72) Inventors: ULDRICK JR., Thomas Smith Tarrytown, New York 10591 (US) MILLER, Elizabeth Tarrytown, New York 10591 (US) (74) Representative: J A Kemp LLP  80 Turnmill Street London EC1M 5QU London EC1M 5QU (GB)